Phase 3 trials suggest that remibrutinib may be a new oral medication for chronic spontaneous urticaria that is both quick-acting and efficient.

Published Date: 14 Aug 2023

Switzerland: Novartis reported positive top-line results from the phase 3 trials REMIX-1 and REMIX-2. Remibrutinib 25 was tested in trials.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot